Gustaf, Aridin (2024) Pengaruh injeksi ranibizumab serial pertama terhadap perubahan makula pada pasien dengan diabetic macular edema di Rumah Sakit Umum Karsa Husada Batu. Undergraduate thesis, Universitas Islam Negeri Maulana Malik Ibrahim.
![]() |
Text (Fulltext)
200701110008.pdf - Accepted Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (2MB) |
Abstract
INDONESIA:
Diabetic macular edema (DME) merupakan komplikasi diabetes melitus yang berkontribusi signifikan terhadap adanya gangguan pengelihatan dan penebalan makula pada orang yang hidup dengan diabetes. Injeksi intravitreal ranibizumab menjadi terapi lini pertama untuk pasien dengan DME. Ranibizumab merupakan salah satu agen anti-VEGF. VEGF berperan penting dalam menginduksi adhesi leukosit pada sel endotel yang menyebabkan terjadinya kerusakan retina, kebocoran darah pada vitreous, dan penebalan makula. Oleh karena itu, penting untuk menghambat kerja VEGF dalam penanganan DME. Penelitian yang dilaksanakan di RSU Karsa Husada Batu sejak bulan Desember 2020 ini, bertujuan untuk mengetahui adanya perubahan ketebalan makula setelah pemberian ranibizumab pada pasien DME. Desain penelitian ini merupakan studi eksperimental dengan pendekatan one group pre-post test design dan didapatkan jumlah sebanyak 67 sampel mata dari 51 orang yang telah dilakukan pemeriksaan menggunakan OCT sebelum diberikan intervensi serial (selama 3 bulan) setelah intervensi. Hasil penelitian menggambarkan bahwa terdapat penurunan ketebalan makula antara pre dan post intervensi (p value = 0.000) dengan rata-rata ketebalan makula sebelum intervensi adalah 548.940 μm dan setelah intervensi sebesar 421.630 μm.
ENGLISH:
Diabetic macular edema (DME) is a complication of diabetes mellitus that contributes significantly to visual impairment and macular thickening in people living with diabetes. Intravitreal injections of ranibizumab have become first-line therapy for patients with DME. Ranibizumab is an anti-VEGF agent. VEGF plays an important role in inducing leukocyte adhesion to endothelial cells which causes retinal damage, blood leakage in the vitreous, and macular thickening. Therefore, it is important to inhibit the action of VEGF in treating DME. This research, which was carried out at Karsa Husada Batu General Hospital since January 2020, aims to determine changes in macular thickness after administering ranibizumab to DME patients. The design of this research was a experimental retrospective study with a one group pre-post test design research design and a total of 67 eye samples were obtained from 51 people who had been examined using OCT before being given serial intervention (for 3 months) after the intervention. The results of the study illustrate that there was a decrease in macular thickness between before and after the intervention (p value = 0.000) with the average macular thickness before the intervention being 548,940 μm and after the intervention being 421,630 μm.
Item Type: | Thesis (Undergraduate) |
---|---|
Supervisor: | Hasan, Yuliono Trika Nur and Ahdi, Iwal Reza |
Keywords: | Ranibizumab; Diabetic Macular Edema; Ketebalan Makula; Macular Thickness. |
Subjects: | 11 MEDICAL AND HEALTH SCIENCES > 1115 Pharmacology and Pharmaceutical Sciences > 111503 Clinical Pharmacy and Pharmacy Practice 11 MEDICAL AND HEALTH SCIENCES > 1117 Public Health and Health Services > 111716 Preventive Medicine |
Departement: | Fakultas Kesehatan dan Ilmu Kedokteran > Jurusan Pendidikan Dokter |
Depositing User: | Aridin Gustaf |
Date Deposited: | 31 Jul 2024 13:34 |
Last Modified: | 31 Jul 2024 13:34 |
URI: | http://etheses.uin-malang.ac.id/id/eprint/66671 |
Downloads
Downloads per month over past year
Actions (login required)
![]() |
View Item |